Simon James Watson

This inventor holds 18 USPTO granted patents and 5 published patent applications, plus 2 CIPO patents and 4 EPO patents, primarily in Pharmaceutical Chemistry. Top assignee: Novartis Ag. Active years: 2005-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Simon James Watson. Retrieved from https://idiyas.com/inventor/simon-james-watson

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 18 (Patent Applications = 5)

% Patents Active = 66.7

CIPO Patents = 2 (Patent Applications = 4)

EPO Patents = 4 (Patent Applications = 8)

Average Co-Inventor Count = 5.8

ph-index = 3

Forward Citations = 47(Granted Patents)

Company Filing History:

18 out of 3,978

Novartis Ag

patents

Years Active: 2005-2018

Loading Chart...

Areas of Expertise:

Phosphatidylinositol 3-Kinase

CRTH2 Antagonists

CXCR2 Antagonists

Pyrrolopyridine Derivatives

Quinuclidine Derivatives

Amino Pyridine Derivatives

Squaramide Derivatives

Quinoline-2-One Derivatives

CXC-Chemokine Receptor Ligands

Organic Compounds

Muscarinic M3 Receptor

Airways Diseases

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10112926 - Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors (2018-10-30),

2. 10004732 - Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors (2018-06-26),

3. 9862711 - Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors (2018-01-09),

4. 9169251 - Pyrrolopyridine derivatives and their use as CRTH2 antagonists (2015-10-27),

5. 9115087 - Squaramide derivatives as CXCR2 antagonist (2015-08-25),

6. 8791256 - Pyrrolopyridine derivatives and their use as CRTH2 antagonists (2014-07-29),

7. 8722925 - Squaramide derivatives as CXCR2 antagonist (2014-05-13),

8. 8470848 - Organic compounds (2013-06-25),

9. 8455645 - Pyrrolopyridine derivatives and their use as CRTH2 antagonists (2013-06-04),

10. 8329754 - Squaramide derivatives as CXCR2 antagonist (2012-12-11),

11. 8288588 - Squaramide derivatives as CXCR2 antagonist (2012-10-16),

12. 8183281 - CXC-chemokine receptor ligands (2012-05-22),

13. 8084463 - Quinuclidine derivatives and their use as muscarinic M3 receptor antagonists (2011-12-27),

14. 7989497 - Squaramide derivatives as CXCR2 antagonist (2011-08-02),

15. 7745462 - Quinoline-2-one derivatives for the treatment of airways diseases (2010-06-29),

Title: Simon James Watson: Innovator in Pharmaceutical Chemistry

Introduction

Simon James Watson is a prominent inventor based in Horsham, GB. He has made significant contributions to the field of pharmaceutical chemistry, holding a total of 18 patents. His work primarily focuses on developing compounds that target specific biological pathways, which can lead to innovative treatments for various diseases.

Latest Patents

Among his latest patents are two notable inventions. The first is related to amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors. This invention provides compounds that inhibit the activity of the PI 3-kinase gamma isoform, which are useful for treating diseases mediated by its activation. The second patent involves amino pyrazine derivatives, which also serve as phosphatidylinositol 3-kinase inhibitors, offering similar therapeutic benefits.

Career Highlights

Simon is currently associated with Novartis AG, a leading global healthcare company. His role at Novartis has allowed him to further his research and development efforts in creating innovative pharmaceutical solutions. His extensive experience and expertise in the field have positioned him as a key player in the industry.

Collaborations

Throughout his career, Simon has collaborated with notable professionals, including Neil John Press and David Andrew Sandham. These collaborations have contributed to the advancement of his research and the successful development of his patented inventions.

Conclusion

Simon James Watson is a distinguished inventor whose work in pharmaceutical chemistry has led to significant advancements in the treatment of diseases. His innovative patents and collaborations reflect his commitment to improving healthcare through scientific research.

Profile summary based on public USPTO records.